Press releases

Stockholm – March 13, 2026 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces the publication of a new real-world study in the peer-reviewed European Journal of Haematology. The study, conducted at the IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy, confirms the efficacy and safety of Pepaxti (melflufen) plus dexamethasone. The heavily pretreated patients, including those refractory to novel immunotherapies, benefitted from Pepaxti’s strong efficacy, the overall response rate (ORR) was 41% with a median progression-free survival (mPFS) of 9.0 months

Stockholm, March 9, 2026 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company specializing in difficult-to-treat cancers, today announces that it has achieved key regulatory agreement with both the Swedish and Norwegian Medical Products Agencies (Läkemedelsverket, MPA and Direktoratet for medisinske produkter, DMP) regarding the design of its planned “Window-of-Opportunity” (WoO) study evaluating a Peptide Drug Conjugate (PDC) in glioblastoma. The study will be conducted in Norway, where DMP has granted fast-track designation

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, ISRAEL, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY SECURITIES IN ONCOPEPTIDES AB (PUBL). SEE ALSO THE SECTION “IMPORTANT INFORMATION” BELOW IN THIS DOCUMENT

Stockholm – February 19, 2026 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today publishes the year-end report for 2025

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, ISRAEL, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY SECURITIES IN ONCOPEPTIDES AB (PUBL). SEE ALSO THE SECTION “IMPORTANT INFORMATION” BELOW IN THIS DOCUMENT

Stockholm – February 12, 2026 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, will publish the report for the fourth quarter and the 2025 year-end report, at 08:00 CET on February 19, 2026

Stockholm, January 15, 2026 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces the net sales for the fourth quarter of 2025 and updates its cash-flow expectations

Stockholm, December 29, 2025 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces new research demonstrating that Pepaxti (melflufen) maintains its anti-myeloma activity in patients with high-risk genetic features, including deletion 17p (del(17p)) and TP53 mutations. These abnormalities are known to be linked to more aggressive disease being less responsive to treatment. The data has been published in an article in Experimental Hematology & Oncology

Stockholm – November 21, 2025 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the composition of the Nomination Committee has been established

Stockholm – November 11, 2025 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that a panel of leading multiple myeloma experts has published clinical recommendations for the optimal use of melflufen (branded in Europe as Pepaxti) in Annals of Hematology. The review article provides practical guidance on patient selection, dosing, and management, reinforcing Pepaxti’s role as an important treatment option for patients with relapsed, refractory multiple myeloma (RRMM)